December 1 2009 Issue

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interview Dr. Massimo Filippi about his paper on oral vs. intravenous methyprednisolone in MS. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about pseudo-myasthenic ptosis. The next part of the podcast is Dr. Alberto Espay interviews Dr. Josep Dalmau for our Lesson of the week toolbox about NMDAR encephalitis. The participants had nothing to disclosure except Drs. Keegan, Filippi, Espay and Dalmau. Dr. Keegan serves as Section Co-Editor for Neurology and the Neurology Podcast Panel.Dr. Filippi serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Genmab A/S; has received funding for travel from Bayer Schering Pharma, Biogen-Dompè AG, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves on editorial boards of the American Journal of Neuroradiology, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Neuroimaging, Journal of Neurology Neurosurgery and Psychiatry, Journal of Neurovirology, Magnetic Resonance Imaging, Multiple Sclerosis, and Neurological Sciences ; serves as a consultant to Bayer Schering Pharma, Biogen-Dompè AG, Genmab A/S, Merck Serono, Pepgen Corporation, and Teva Pharmaceutical Industries Ltd.; serves on speakers' bureaus for Bayer Schering Pharma, Biogen-Dompè AG, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; and receives research support from Bayer Schering Pharma, Biogen-Dompè AG, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd., Fondazione Italiana Sclerosi Multipla, and Fondazione Mariani. Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.Dr. Dalmau has received honoraria for lectures not funded by industry; receives research support from EUROIMMUN and the NIH/NCI [RO1CA107192 (PI) and RO1CA89054-06A2 (PI)]; has received license fee payments from EUROIMMUN for an NMDA receptor autoantibody test (patent pending PCT/US07/18092, filed: August 15, 2007); and has received royalty payments and may accrue revenue for US Patent 6,387,639;, issued: May 14th, 2002: Patent for Ma2 autoantibody test.